Proteomic Protocol in Esophageal Adenocarcinoma

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1756)

Abstract

The technique of surface-enhanced laser desorption/ionization time-of-flight SELDI-TOF mass spectrometry could be used to establish serum or plasma proteomic profiles in esophageal adenocarcinoma. The protein profiles in patients may be used to predict survival and monitor response to chemotherapy in patients with esophageal adenocarcinoma. Here, a protocol for sample preparation from esophageal adenocarcinoma, analysis of proteomic profiles, and collection of protein fractions for identification of significant peaks is presented.

Key words

Proteomic profile Mass spectrometry Protein chips SELDI-TOF MS Protein fractionation 

References

  1. 1.
    Cahill DJ (2001) Protein and antibody arrays and their medical applications. J Immunol Methods 250:81–91CrossRefGoogle Scholar
  2. 2.
    Plebani M (2005) Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 357:13–22Google Scholar
  3. 3.
    Colantonio DA, Chan DW (2005) The clinical application of proteomics. Clin Chim Acta 357:151–158CrossRefGoogle Scholar
  4. 4.
    Hu L, Ye M, Jiang X, Feng S, Zhou H et al (2007) Advances in hyphenated analytical techniques for shotgun proteome and peptidome analysis—a review. Anal Chim Acta 598:193–204CrossRefGoogle Scholar
  5. 5.
    Pastwa E, Somiari SB, Czyz M, Somiari R (2007) Proteomics in human cancer research. Proteomics Clin Appl 1:4–17CrossRefGoogle Scholar
  6. 6.
    Soldes OS, Kuick RD, Thompson IA, Hughes SJ, Orriger MB, Lannettoni MD, Hanash SM, Beer DG (1999) Differential expression of Hsp27 in normal oesophagus, Barrett’s metaplasia and esophageal adenocarcinomas. Br J Cancer 79:595–603CrossRefGoogle Scholar
  7. 7.
    Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS et al (2000) Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60:6293–6297PubMedGoogle Scholar
  8. 8.
    Hayashida Y, Honda K, Osaka Y, Hara T, Umaki T, Tsuchida A et al (2005) Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res 11:8042–8047CrossRefGoogle Scholar
  9. 9.
    Kelly P, Appleyard V, Murray K, Paulin F, Lamont D, Baker L et al (2010) Detection of esophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer 103:232–238CrossRefGoogle Scholar
  10. 10.
    Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D, Thompson A (2012) Pre-treatment plasma proteomic markers associated with survival in esophageal cancer. Br J Cancer 106:955–961CrossRefGoogle Scholar
  11. 11.
    Hortin GL, Sviridov D, Anderson NL (2008) High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypetide abundance. Clin Chem 54:1608–1616CrossRefGoogle Scholar
  12. 12.
    Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC (2005) Differences among techniques for high-abundance protein depletion. Proteomics 5:3304–3313CrossRefGoogle Scholar
  13. 13.
    Granger J, Siddiqui J, Copeland S, Remick D (2005) Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 5:4713–4718CrossRefGoogle Scholar
  14. 14.
    Pappin DJ, Hojrup P, Bleasby AJ (1993) Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 3:327–332CrossRefGoogle Scholar
  15. 15.
    Mascot Server (2016) Matrix Science, London. http://www.matrixscience.com. Accessed 15 Jan 2017

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Axis ShieldDundeeUK

Personalised recommendations